glp-1prescriptions

Care that continues
Independent editorial information · not individual medical advice

Commercial pages may contain paid referral links. Compare the full payment terms and licensed-care details before enrollment.

Denied by One Telehealth Platform, Approved by Another: Why Criteria Differ

GLP-1 Prescriptions Editorial Team · July 17, 2026 · 8 min read
Affiliate Disclosure: This site contains affiliate links to telehealth providers. If you click a link and make a purchase, we may receive a commission at no extra cost to you. All opinions are our own. Links marked "Paid link" are sponsored placements. See our full disclosure.

Not All Platforms Use the Same Rulebook

Each GLP-1 telehealth platform develops its own clinical protocols — the rules their prescribers follow when evaluating patients. While all platforms operate within the FDA's approved indication framework, there's significant variation in how they interpret and apply those criteria.

Common differences include: BMI thresholds (some platforms require BMI ≥ 30, others accept BMI ≥ 27 with comorbidities, and a few will prescribe at lower BMIs with clinical justification), contraindication lists (some exclude conditions that others evaluate case-by-case), required labs or screenings (some platforms require recent bloodwork, others don't), and the depth of medical evaluation (from comprehensive telehealth visits to brief questionnaire-only approvals).

Why Stricter Isn't Always Better

It's tempting to assume that stricter platforms are more responsible, but the Yale JAMA study revealed the opposite end of the spectrum — platforms that approve almost everyone with minimal clinical evaluation. The reality is that responsible prescribing isn't about being maximally strict or maximally permissive. It's about matching treatment decisions to individual patient circumstances.

A platform that denies you because your BMI is 28.5 instead of 30, despite documented comorbidities, isn't being responsible — it's being rigid. A platform that approves you in 5 minutes without asking about your thyroid history isn't being accessible — it's being careless.

Editor's Choice

Embody

Top Pick — $400 CPA

From $249/mo

Injectable semaglutide only. Compounded — not FDA-approved.

Compare current GLP-1 options →

What to Do After a Denial

Ask for the specific reason. "Your application was denied" isn't helpful. Ask which criteria you didn't meet. The answer tells you whether to try another platform or address a clinical issue first.

Try another platform with your records. If Platform A denied you for BMI (borderline) but you have significant comorbidities, Platform B's protocol may weigh comorbidities more heavily. Bring your denial letter and medical records to give the new prescriber full context.

Consider a non-platform prescriber. Your PCP or an obesity medicine specialist isn't bound by any platform's protocol. They evaluate you as an individual patient and make clinical decisions accordingly.

Red Flags on Both Sides

Red flags in a denial: No explanation given. Denial is clearly based on a blanket policy rather than clinical evaluation. No appeal or reconsideration process available.

Red flags in an approval: Approved without asking about thyroid history, eating disorder screening, or current medications. No medical professional identified by name. Approval took less than 5 minutes with no clinical interaction.

The right platform evaluates you individually, explains its reasoning, and makes a clinical decision that accounts for your specific health profile — whether that decision is to approve or deny.

Sponsored partner · Compounded semaglutide listingHealthRX — semaglutide

Explore HealthRX’s compounded semaglutide listing. Compounded medications are not FDA-approved; verify the current legal pathway, pharmacy and total price.

Explore HealthRX — semaglutide ↗Eligibility and prices must be verified directly. Compounded GLP-1 products are not FDA-approved.
Sponsored partner · Compounded tirzepatide listingHealthRX — tirzepatide

Explore HealthRX’s compounded tirzepatide listing. Compounded medications are not FDA-approved; verify the current legal pathway, pharmacy and total price.

Explore HealthRX — tirzepatide ↗Eligibility and prices must be verified directly. Compounded GLP-1 products are not FDA-approved.
Medical Disclaimer: This content is for informational purposes only and does not constitute medical advice, diagnosis, or treatment. GLP-1 receptor agonists are prescription medications with potential side effects including nausea, vomiting, diarrhea, and in rare cases, pancreatitis or thyroid tumors. Do not use if you have a personal or family history of medullary thyroid carcinoma (MTC) or Multiple Endocrine Neoplasia syndrome type 2 (MEN 2). Always consult a licensed healthcare provider before starting any medication. Compounded medications are not FDA-approved for safety, efficacy, or quality.